Peptide Reference

CJC-1295

CJC-1295 with DAC

A growth hormone releasing hormone (GHRH) analog that stimulates the pituitary to release growth hormone. The 'with DAC' version has a longer half-life due to drug affinity complex.

Status

research

Category

growth hormone

Typical cost

$50-120/vial (2mg with DAC)

Mechanism

Binds to GHRH receptors in the pituitary, increasing both the frequency and amplitude of growth hormone pulses. The DAC component extends half-life to approximately 6-8 days. Increases IGF-1 levels.

Potential benefits

  • Elevated growth hormone
  • Increased IGF-1
  • Muscle growth
  • Fat loss
  • Improved sleep
  • Enhanced recovery
  • Better skin and hair

Reported side effects

  • Water retention
  • Numbness/tingling
  • Injection site reactions
  • Tiredness
  • Reduced insulin sensitivity

Common dosing references

subcutaneous

1000-2000mcg · 2x weekly

8-12 weeks

subcutaneous (without DAC)

100-300mcg · 1-3x daily

8-12 weeks

Research notes

CJC-1295 pharmacokinetics

2005

Demonstrated significantly extended half-life and sustained GH elevation with DAC version

CJC-1295 in healthy adults

2006

Showed significant increases in GH and IGF-1 levels with good tolerability

Regulatory and sourcing notes

Research chemical only. Not FDA-approved. Not available by prescription.

Research peptide only. 'With DAC' versions are longer-acting. Often combined with Ipamorelin in 'CJC/Ipam' stack.

Find peptide-aware clinics

Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.

Search Local Clinics

Related peptides

IpamorelinSermorelinTesamorelinGHRP-6